Pulmonx (LUNG)
NASDAQ:LUNG
Want to see LUNG full AI Analyst Report?
LUNG Stock Chart & Stats
$1.80
-$0.17(-2.57%)
At close: 4:00 PM EST
$1.80
-$0.17(-2.57%)
Day’s Range― - ―
52-Week Range$1.13 - $3.88
Previous CloseN/A
Volume95.69K
Average Volume (3M)308.20K
Market Cap
$57.86M
Enterprise Value$64.41M
Total Cash (Recent Filing)$61.57M
Total Debt (Recent Filing)$56.29M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 05, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding42,237,200
10 Day Avg. Volume245,979
30 Day Avg. Volume308,202
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.66
Price to Sales (P/S)0.99
P/FCF Ratio-2.73
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit0.96
Enterprise Value/Ebitda-1.33
Forecast
1Y Price Target
$3.50Price Target Upside94.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.14
Revenue Forecast (FY)$90.87M
Bulls Say, Bears Say
Bulls Say
High Gross MarginSustained mid-70s gross margins reflect a high-margin per-procedure device model with favorable unit economics. Durable gross profitability cushions the business against revenue volatility, enabling incremental operating leverage as sales scale and supporting pathway to break-even if SG&A and R&D remain controlled.
Cost Reductions & Expense ControlA >10% reduction in ongoing operating expenses demonstrates management discipline that materially lowers the cash burn baseline. This structural expense improvement increases runway, reduces reliance on external financing, and raises the probability that revenue stabilization will translate into improved adjusted EBITDA and eventual profitability.
Clinical Pipeline Expands TAMProgress in the CONVERT II pivotal trial for AeriSeal represents a structural growth lever: a successful outcome and subsequent commercialization could broaden the patient population and raise long-term procedure volumes. This pipeline-driven TAM expansion diversifies revenue beyond the core valve and supports multi-year growth potential.
Bears Say
Revenue DeclineA year-over-year revenue decline signals persistent demand headwinds for a procedure-driven business where growth depends on clinician adoption and referral patterns. Prolonged revenue weakness undermines operating leverage, increases financing needs, and raises uncertainty about timing to return to sustainable growth.
Weak Cash Flow & Rising LeverageNegative operating and free cash flow combined with debt exceeding equity indicate constrained financial flexibility and ongoing funding dependence. Elevated leverage increases refinancing and covenant risk, and secured credit facilities add repayment and warrant pressures that can dilute optionality for strategic investments.
Execution & Regulatory Timing RiskThe growth plan hinges on salesforce productivity and regulatory timing in China. Typical 6–9 month rep ramps and a pending China registration renewal create durable execution risk: delays or slower-than-expected adoption would prolong cash burn, hinder international recovery, and pressure achievement of stated guidance.
Pulmonx News
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $1.13 and its highest was $3.88 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is $57.86M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Aug 05, 2026 which is in 52 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Apr 29, 2026. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.327 by -$0.003.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.28.
How many shares outstanding does Pulmonx have?
Pulmonx has 42,237,200 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.327. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in LUNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.50 (94.44% Upside)
$3.50 (94.44% Upside)
Hedge Fund Trend
Decreased
By 2.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $144.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.2%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.30%
12-Months-Change
Fundamentals
Return on Equity
-82.79%
Trailing 12-Months
Asset Growth
-20.13%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
LUNG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call mixes clear near-term challenges (Q1 revenue declines, China registration-driven international disruption, ongoing net losses) with several meaningful positive developments: improved gross margin, cost reductions lowering operating expense trajectory, strengthened liquidity via a $60M credit facility, addition of U.S. treating centers and filled sales roles, and progressing pivotal clinical enrollment that could expand TAM by ~20%. Management reiterated full-year guidance of $90M–$92M and expects sequential improvement with a return to growth in H2 2026. The narrative is execution- and timing-dependent but supported by concrete operational and financial actions that materially reduce downside risk.View all LUNG earnings summariesLUNG Stock 12 Month Forecast
Average Price Target
$3.50
▲(94.44% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Ownership Overview
14.06% Insiders
17.24% Mutual Funds
31.62% Other Institutional Investors
29.15% Public Companies and
Individual Investors